These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24392977)

  • 21. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Molenberghs M
    Pharm Stat; 2013; 12(1):1-6. PubMed ID: 23193075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subgroups: time to go back to basic statistical principles?
    Keene ON; Garrett AD
    J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Representation of South Asian people in randomised clinical trials: analysis of trials' data.
    Mason S; Hussain-Gambles M; Leese B; Atkin K; Brown J
    BMJ; 2003 Jun; 326(7401):1244-5. PubMed ID: 12791739
    [No Abstract]   [Full Text] [Related]  

  • 27. Screening, recruiting and predicting retention of participants in a multisite HIV prevention trial. NIMH Multisite HIV Prevention Trial.
    AIDS; 1997 Dec; 11 Suppl 2():S13-9. PubMed ID: 9475707
    [No Abstract]   [Full Text] [Related]  

  • 28. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A guide to interpretation of studies investigating subgroups of responders to physical therapy interventions.
    Hancock M; Herbert RD; Maher CG
    Phys Ther; 2009 Jul; 89(7):698-704. PubMed ID: 19465372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional consistency and sample size considerations in a multiregional equivalence trial.
    Wu SC; Xu JF; Zhang XJ; Li ZW; He J
    Pharm Stat; 2020 Nov; 19(6):897-908. PubMed ID: 32716135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
    Choi L; Dominici F; Zeger SL; Ouyang P
    Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing multiregional trials under the discrete random effects model.
    Lan KK; Pinheiro J; Chen F
    J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From randomized trials to registry studies: translating data into clinical information.
    Brown ML; Gersh BJ; Holmes DR; Bailey KR; Sundt TM
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):613-20. PubMed ID: 18679381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two new covariate adjustment methods for non-inferiority assessment of binary clinical trials data.
    Hou Y; Ding V; Li K; Zhou XH
    J Biopharm Stat; 2011 Jan; 21(1):77-93. PubMed ID: 21191856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 38. What we learned about trials from the European Carotid Stent Trials.
    Zeebregts CJ; Cheshire NJ; Bosiers M; Cao P; Verhoeven EL
    Ann Vasc Surg; 2008 Jan; 22(1):159-61. PubMed ID: 18083342
    [No Abstract]   [Full Text] [Related]  

  • 39. Group sequential enrichment design incorporating subgroup selection.
    Magnusson BP; Turnbull BW
    Stat Med; 2013 Jul; 32(16):2695-714. PubMed ID: 23315698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.